Joel Sobecki
Family · Fostoria, OHNPI 1104181197
Payments from drug & device makers
Across 57 payments — averaging $20.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$257
- AbbVie$119
- Phathom Pharmaceuticals, Inc.$107
- Lilly USA, LLC$97
- AstraZeneca$88
- Johnson & Johnson$66
- plus $446 from 18 others
What the payments were for
- Food & beverage$1,178100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 9 | $257 |
| AbbVie | 6 | $119 |
| Phathom Pharmaceuticals, Inc. | 3 | $107 |
| Lilly USA, LLC | 6 | $97 |
| AstraZeneca | 6 | $88 |
| Johnson & Johnson | 1 | $66 |
| Otsuka America Pharmaceutical, Inc. | 3 | $51 |
| Pfizer | 2 | $44 |
| Abbott | 2 | $38 |
| Exact Sciences | 2 | $33 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| GSK | 2 | $28 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| Merck | 1 | $21 |
| Boehringer Ingelheim | 1 | $20 |
| Dexcom, Inc. | 1 | $20 |
| Verona Pharma, Inc. | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Vertex | 1 | $15 |
| Amgen | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Shield Therapeutics Inc | 1 | $14 |
| Dynavax Technologies Corporation | 1 | $13 |
How this compares
$1,178 in reported general payments places this provider in the 70th percentile of 6,812 family providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 50 | $57,119 |
| OzempicSemaglutide | 53 | $53,405 |
| JardianceEmpagliflozin | 40 | $42,116 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 59 | $40,765 |
| JanuviaSitagliptin Phosphate | 26 | $36,243 |
| TrulicityDulaglutide | 33 | $34,579 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $30,812 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 45 | $30,317 |
| FarxigaDapagliflozin Propanediol | 23 | $24,730 |
| MounjaroTirzepatide | 18 | $19,602 |
| VraylarCariprazine Hcl | 13 | $18,480 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $17,056 |
| Spiriva RespimatTiotropium Bromide | 22 | $15,686 |
| TrintellixVortioxetine Hydrobromide | 18 | $12,182 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 29 | $11,038 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat | $20 | $88,119107 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $88 | $65,49582 claims |
| Novo NordiskOzempic, Rybelsus | $257 | $63,88564 claims |
| PfizerEliquis | $44 | $57,11950 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $97 | $54,18151 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta | $28 | $44,90868 claims |
| MerckJanuvia | $21 | $36,24326 claims |
| AbbVieVraylar | $119 | $18,48013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,812 family providers in Ohio.
Other family in Fostoria
- Eileen FauldsLewis Center$991K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
- Florence StewartNew Albany$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.